Frank A.  D'Amelio net worth and biography

Frank D'Amelio Biography and Net Worth

CFO & Exec. VP of Pfizer
Frank A. D'Amelio was initially elected to the Board in September 2003. Mr. D'Amelio was formerly Executive Vice President, Chief Financial Officer at Pfizer Inc. having held this position from January 2022 until May 2022. Mr. D’Amelio began his career at Pfizer in 2007 and since then has held various roles of increasing responsibility, including, SVP & Chief Financial Officer (September 2007-December 2010), Executive Vice President, Business Operations and Chief Financial Officer (January 2011-October 2018) and Chief Financial Officer and Executive Vice President, Global Supply (November 2018-December 2021). Prior to that, Mr. D’Amelio was Senior Executive Vice President of Integration and Chief Administrative Officer at Alcatel-Lucent from December 2006 to August 2007, and Chief Operating Officer of Lucent Technologies Inc. from February 2006 to November 2006. From May 2001 until January 2006, he was Executive Vice President, Administration and Chief Financial Officer of Lucent. Mr. D’Amelio also serves on the Board of Directors of Zoetis, Inc. and on the board of the Independent Colleges and Universities of New Jersey.

The Board believes that Mr. D’Amelio’s skills, global experience and proven leadership in both financial and operational roles contribute greatly to the Board’s composition. As a senior executive at various global companies undergoing the kind of rapid and complex changes that the Company has undertaken in response to the rapidly changing markets and regulatory environment, Mr. D’Amelio has extensive knowledge of the capital markets as well as broad experience working with the investment community, regulatory bodies and rating agencies.

How do I contact Frank A. D'Amelio?

The corporate mailing address for Mr. D'Amelio and other Pfizer executives is 235 EAST 42ND STREET, NEW YORK NY, 10017. Pfizer can also be reached via phone at (212) 733-2323. Learn More on Frank A. D'Amelio's contact information.

Has Frank A. D'Amelio been buying or selling shares of Pfizer?

Frank A. D'Amelio has not been actively trading shares of Pfizer during the last ninety days. Learn More on Frank A. D'Amelio's trading history.

Who are Pfizer's active insiders?

Pfizer's insider roster includes Ronald Blaylock (Director), Albert Bourla (DVM), Loretta Cangialosi (VP), William Carapezzi, Jr. (EVP), Albert D.V.M. (DVM), Frank Damelio (EVP), Frank D'Amelio (CFO & Exec. VP ), Jennifer Damico (SVP), Jennifer Damico (SVP), Scott Gottlieb (Director), Rady Johnson (Insider), Douglas Lankler (EVP), Alexander Mackenzie (EVP), Laurie Olson (Insider), Ian Read (CEO), Dawn Rogers (EVP), Sally Susman (Insider), and John Young (Insider). Learn More on Pfizer's active insiders.

Are insiders buying or selling shares of Pfizer?

In the last year, Pfizer insiders bought shares 1 times. They purchased a total of 1,000 shares worth more than $28,240.00. The most recent insider tranaction occured on October, 30th when Director Scott Gottlieb bought 1,000 shares worth more than $28,240.00. Insiders at Pfizer own 0.1% of the company. Learn More about insider trades at Pfizer.

Information on this page was last updated on 10/30/2024.

Frank A. D'Amelio Insider Trading History at Pfizer

See Full Table

Frank A. D'Amelio Buying and Selling Activity at Pfizer

This chart shows Mr. Frank A. D'Amelio's buying and selling at Pfizer by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Pfizer Company Overview

Pfizer logo
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Read More

Today's Range

Now: $26.36
Low: $25.70
High: $26.49

50 Day Range

MA: $26.82
Low: $24.80
High: $29.66

2 Week Range

Now: $26.36
Low: $24.48
High: $31.54

Volume

116,162,070 shs

Average Volume

39,035,680 shs

Market Capitalization

$149.38 billion

P/E Ratio

35.62

Dividend Yield

6.65%

Beta

0.65